Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. DAWN
stocks logo

DAWN

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Intellectia AI SwingMax
Intellectia AI SwingMax

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
44.10M
+51.03%
-0.194
-69.16%
50.86M
+65.35%
-0.250
-28.57%
55.58M
+63.92%
-0.220
-24.14%
Estimates Revision
The market is revising Upward the revenue expectations for Day One Biopharmaceuticals, Inc. (DAWN) for FY2025, with the revenue forecasts being adjusted by 2.23% over the past three months. During the same period, the stock price has changed by 10.46%.
Revenue Estimates for FY2025
Revise Upward
up Image
+2.23%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
down Image
-17.96%
In Past 3 Month
Stock Price
Go Up
up Image
+10.46%
In Past 3 Month
Wall Street analysts forecast DAWN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for DAWN is 23.57 USD with a low forecast of 16.00 USD and a high forecast of 34.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
8 Analyst Rating
Wall Street analysts forecast DAWN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for DAWN is 23.57 USD with a low forecast of 16.00 USD and a high forecast of 34.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
7 Buy
1 Hold
0 Sell
Strong Buy
Current: 8.340
sliders
Low
16.00
Averages
23.57
High
34.00
Current: 8.340
sliders
Low
16.00
Averages
23.57
High
34.00
JPMorgan
NULL -> Overweight
maintain
$26 -> $27
2025-11-07
Reason
JPMorgan
Price Target
$26 -> $27
2025-11-07
maintain
NULL -> Overweight
Reason
JPMorgan raised the firm's price target on Day One Biopharmaceuticals to $27 from $26 and keeps an Overweight rating on the shares. The firm updated the company's model.
Piper Sandler
Overweight
maintain
$25 -> $26
2025-11-05
Reason
Piper Sandler
Price Target
$25 -> $26
2025-11-05
maintain
Overweight
Reason
Piper Sandler raised the firm's price target on Day One Biopharmaceuticals to $26 from $25 and keeps an Overweight rating on the shares following quarterly results. The firm thinks valuation provides an attractive entry point into Day One ahead of continued commercial execution, additional long-term data, and eventual 1L pLGG data in 2027.
Piper Sandler
Overweight
initiated
$25
2025-08-19
Reason
Piper Sandler
Price Target
$25
2025-08-19
initiated
Overweight
Reason
Piper Sandler initiated coverage of Day One Biopharmaceuticals with an Overweight rating and $25 price target. Piper thinks the stock move following the first two 2025 earnings reports is overdone and that these early decelerations of Ojemda are artifacts of a unique cancer indication wherein the prescribing physicians are risk-averse and slow to adopt novel therapies, the analyst tells investors in a research note. The firm continues to believe the clinical data will support strong penetration longer term.
Piper Sandler
Overweight
initiated
$25
2025-08-18
Reason
Piper Sandler
Price Target
$25
2025-08-18
initiated
Overweight
Reason
Piper Sandler initiated coverage of Day One Biopharmaceuticals with an Overweight rating and $25 price target.
H.C. Wainwright
Andres Maldonado
Buy
downgrade
$36 -> $25
2025-08-06
Reason
H.C. Wainwright
Andres Maldonado
Price Target
$36 -> $25
2025-08-06
downgrade
Buy
Reason
H.C. Wainwright analyst Andres Maldonado lowered the firm's price target on Day One Biopharmaceuticals to $25 from $36 and keeps a Buy rating on the shares following the Q2 report. The firm reduced estimates for the Ojemda launch.
BofA
Buy
downgrade
$20 -> $17
2025-08-06
Reason
BofA
Price Target
$20 -> $17
2025-08-06
downgrade
Buy
Reason
BofA lowered the firm's price target on Day One Biopharmaceuticals to $17 from $20 and keeps a Buy rating on the shares. The firm estimates approximately 25-35 new patients added per month in Q1 and assuming a flat growth rate of patients over the quarter sees about 18 new patient starts per month in Q2, which it calls out as "significantly less than the lower end of our estimate in 1Q." The new FY25 guidance of $140M-$150M net product revenue "seems to reflect a slowdown in growth," which will be something to watch as Day One focuses on improving both breadth and depth of prescriber adoption, the analyst added.
See All Ratings

Valuation Metrics

The current forward P/E ratio for Day One Biopharmaceuticals Inc (DAWN.O) is -13.88, compared to its 5-year average forward P/E of -8.23. For a more detailed relative valuation and DCF analysis to assess Day One Biopharmaceuticals Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-8.23
Current PE
-13.88
Overvalued PE
-4.76
Undervalued PE
-11.70

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-5.22
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
-0.88
Undervalued EV/EBITDA
-9.56

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
477.36
Current PS
0.00
Overvalued PS
2327.55
Undervalued PS
-1372.83
AI Stock Picker
AI Stock Picker

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Financial AI Agent
Financial AI Agent

DAWN News & Events

Events Timeline

(ET)
2025-11-24
08:18:07
Day One Biopharmaceuticals Reveals Three-Year Follow-Up Results from FIREFLY-1 Study
select
2025-11-13 (ET)
2025-11-13
10:08:45
Oppenheimer finds Day One's $285M investment in Mersana 'intriguing'
select
2025-11-13
06:03:28
Day One Biopharmaceuticals to purchase Mersana Therapeutics for a total of up to $285 million
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
4.0
11-24Benzinga
Needham Affirms Buy Rating for Day One Biopharmaceutical, Keeps $16 Price Target Intact

  • Real-time Intelligence: Benzinga Pro offers the fastest news alerts for traders, helping them stay informed and make timely decisions in the stock market.

  • Exclusive Content: The platform provides exclusive stories and insights generated by Benzinga reporters, enhancing the trading experience for its users.

  • Community Engagement: Over 10,000 serious traders are part of the Benzinga Pro community, indicating a robust network for sharing market intelligence.

  • Market Winning Tools: Benzinga Pro is designed to equip traders with the tools and information necessary to succeed in the markets daily.

[object Object]
Preview
8.5
11-13Benzinga
Day One Biopharma Enhances Oncology Portfolio Through $285 Million Acquisition of Mersana

  • Acquisition Announcement: Day One Biopharmaceuticals has agreed to acquire Mersana Therapeutics for a total deal value of up to approximately $285 million, with an upfront cash consideration of $25 per share and additional contingent payments.

  • Focus on Pediatric Cancers: Day One is dedicated to developing treatments for pediatric cancers, with a strong pipeline including the drug tovorafenib (Ojemda), which has seen significant revenue growth and increased prescription rates.

  • Mersana's Development Potential: The acquisition allows Day One to support the development of Mersana's Emi-Le for treating adenoid cystic carcinoma, addressing a significant unmet medical need.

  • Market Reaction: Following the announcement, Mersana Therapeutics shares surged by over 206%, while Day One Biopharmaceuticals shares experienced a decline of nearly 6%.

[object Object]
Preview
8.5
11-13TipRanks
What’s Driving the Increase in Mersana Therapeutics Stock (MRSN) Today?

  • Acquisition Announcement: Mersana Therapeutics (MRSN) stock surged after announcing a $129 million acquisition deal with Day One Biopharmaceuticals (DAWN), potentially reaching $285 million based on certain milestones.

  • Tender Offer Details: Day One will offer $25 per share in cash for MRSN stock, with additional contingent value rights of up to $30.25 per share if specific clinical and regulatory milestones are achieved.

  • Market Reaction: MRSN shares rose 202.14% in pre-market trading, despite a year-to-date decline of 75.19%. Heavy trading activity was noted, with over 684,000 shares traded compared to a three-month average of 62,000.

  • Analyst Ratings: The consensus rating for Mersana Therapeutics is a Strong Buy, with an average price target of $40, indicating a potential upside of 350.96% for the stock.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Day One Biopharmaceuticals Inc (DAWN) stock price today?

The current price of DAWN is 8.34 USD — it has increased 0.36 % in the last trading day.

arrow icon

What is Day One Biopharmaceuticals Inc (DAWN)'s business?

Day One Biopharmaceuticals, Inc. is a commercial-stage biopharmaceutical company focused on developing and commercializing targeted therapies for people of all ages with life-threatening diseases. The Company partners with clinical oncologists, families, and scientists to identify, acquire, and develop cancer treatments. The Company’s commercial product, OJEMDA (tovorafenib), is an oral, brain-penetrant, selective type II rapidly accelerated fibrosarcoma (RAF) kinase inhibitor of mutant BRAF V600, wild-type BRAF, and wild-type CRAF kinases. Its pipeline product candidates include DAY301 and VRK1 program. The DAY301 candidate is a PTK7 targeted ADC composed of a novel humanized anti-PTK7 immunoglobulin G1 monoclonal antibody (mAb), conjugated with a topoisomerase I inhibitor through a stable and hydrophilic modified valine-alanine (VA) cleavable linker. Its VRK1 program is a novel target involved in the regulation of cell division and DNA damage repair.

arrow icon

What is the price predicton of DAWN Stock?

Wall Street analysts forecast DAWN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for DAWN is 23.57 USD with a low forecast of 16.00 USD and a high forecast of 34.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Day One Biopharmaceuticals Inc (DAWN)'s revenue for the last quarter?

Day One Biopharmaceuticals Inc revenue for the last quarter amounts to 39.80M USD, decreased -57.56 % YoY.

arrow icon

What is Day One Biopharmaceuticals Inc (DAWN)'s earnings per share (EPS) for the last quarter?

Day One Biopharmaceuticals Inc. EPS for the last quarter amounts to -0.19 USD, decreased -150.00 % YoY.

arrow icon

What changes have occurred in the market's expectations for Day One Biopharmaceuticals Inc (DAWN)'s fundamentals?

The market is revising Upward the revenue expectations for Day One Biopharmaceuticals, Inc. (DAWN) for FY2025, with the revenue forecasts being adjusted by 2.23% over the past three months. During the same period, the stock price has changed by 10.46%.
arrow icon

How many employees does Day One Biopharmaceuticals Inc (DAWN). have?

Day One Biopharmaceuticals Inc (DAWN) has 181 emplpoyees as of December 05 2025.

arrow icon

What is Day One Biopharmaceuticals Inc (DAWN) market cap?

Today DAWN has the market capitalization of 856.31M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free